Given the success of kinase inhibitors in the treatment of chronic myeloid leukemia, the discovery of activating JAK2 point mutations and JAK2 fusion genes in ALL, was a breakthrough for potential targeted therapies. This evidence concerns the gene JAK2 and chronic myelogenous leukemia, BCR-ABL1 positive.